ValuEngine Downgrades Prothena (PRTA) to Sell

ValuEngine lowered shares of Prothena (NASDAQ:PRTA) from a hold rating to a sell rating in a research note published on Tuesday.

Several other brokerages have also recently weighed in on PRTA. Barclays decreased their price objective on Prothena from $70.00 to $50.00 and set an overweight rating for the company in a report on Thursday, April 5th. BidaskClub upgraded Prothena from a strong sell rating to a sell rating in a report on Thursday, January 11th. Cantor Fitzgerald restated a buy rating and issued a $65.00 price objective on shares of Prothena in a report on Sunday, February 4th. Zacks Investment Research cut Prothena from a hold rating to a sell rating in a report on Tuesday, January 9th. Finally, Deutsche Bank restated a buy rating on shares of Prothena in a report on Wednesday, March 21st. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and ten have given a buy rating to the company. The company currently has an average rating of Buy and an average price target of $73.18.

Shares of NASDAQ PRTA opened at $37.60 on Tuesday. The stock has a market capitalization of $1,461.98, a PE ratio of -9.24 and a beta of 2.70. Prothena has a fifty-two week low of $27.19 and a fifty-two week high of $70.00.



Prothena (NASDAQ:PRTA) last announced its quarterly earnings data on Wednesday, February 14th. The biotechnology company reported ($1.24) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.48) by $0.24. The company had revenue of $0.23 million during the quarter, compared to analysts’ expectations of $0.27 million. Prothena had a negative return on equity of 33.37% and a negative net margin of 556.84%. Prothena’s revenue for the quarter was up 33.9% compared to the same quarter last year. During the same quarter last year, the company earned ($1.41) EPS. sell-side analysts expect that Prothena will post -5.34 earnings per share for the current fiscal year.

Institutional investors have recently bought and sold shares of the stock. Fieldpoint Private Securities LLC bought a new position in Prothena during the third quarter worth about $162,000. First Trust Advisors LP bought a new position in Prothena during the third quarter worth about $212,000. HBK Investments L P bought a new position in Prothena during the fourth quarter worth about $213,000. Jefferies Group LLC bought a new position in Prothena during the fourth quarter worth about $292,000. Finally, Capital Fund Management S.A. bought a new position in Prothena during the fourth quarter worth about $330,000.

ILLEGAL ACTIVITY WARNING: This news story was first reported by Dakota Financial News and is owned by of Dakota Financial News. If you are reading this news story on another website, it was stolen and reposted in violation of international trademark & copyright laws. The original version of this news story can be read at https://dakotafinancialnews.com/2018/04/13/valuengine-downgrades-prothena-prta-to-sell.html.

Prothena Company Profile

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on the discovery, development, and commercialization of novel immunotherapies for the treatment of diseases in the neuroscience and orphan categories. The company is developing antibody-based product candidates that include NEOD001, a monoclonal antibody that is in Phase III and Phase IIb clinical trials for the treatment of AL amyloidosis; PRX002/RG7935 that is in Phase II clinical trial for treating Parkinson's disease and other related synucleinopathies; and PRX004, a monoclonal antibody that is under preclinical development for the treatment of ATTR Amyloidosis.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Prothena (NASDAQ:PRTA)

Receive News & Ratings for Prothena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply